The second act of R&D race for anti-obesity drugs

The second act of the research and development race for anti-obesity drugs, which is said to be a 20-trillion-yen market, is up. This is the development of deterrent drugs for the expanded indications and the chronic side-effect of sarcopenia. Report on the frontline.
https://miyata-bio.net/column/0000416/